Sulfide:Quinone Oxidoreductase Deficiency (SQORD) — Comprehensive Disease Characteristics Report

Disease: Sulfide Quinone Oxidoreductase Deficiency MONDO: MONDO:0030982 · OMIM (phenotype): #619221 · Gene: SQOR (OMIM 617658) Category: Mendelian — autosomal-recessive mitochondrial (inborn error of hydrogen-sulfide catabolism) Report date:* 2026-10-08

Summary

Sulfide:quinone oxidoreductase deficiency (SQORD; MONDO:0030982, OMIM #619221) is an ultra-rare, autosomal-recessive inborn error of mitochondrial hydrogen-sulfide (H₂S) catabolism caused by biallelic loss-of-function variants in SQOR (15q21.1; HGNC:20390; UniProt Q9Y6N5). SQOR encodes the committed first enzyme of mitochondrial sulfide oxidation — an inner-membrane FAD flavoprotein (EC 1.8.5.4) that oxidizes H₂S and funnels the electrons into ubiquinone/Coenzyme Q, coupling sulfide detoxification to the respiratory chain.

When SQOR is lost, endogenous and gut-microbiome-derived H₂S can no longer be cleared and accumulates to concentrations that inhibit complex IV (cytochrome c oxidase). The result is an isolated, functional complex IV deficiency — activity falls while complex IV protein level and assembly remain normal — producing bioenergetic failure in the most oxygen- and energy-dependent tissues, above all the brain. Clinically this manifests as a childhood-onset, infection-triggered Leigh-like metabolic encephalopathy with coma, hypotonia, seizures, lactic acidosis, elevated brain lactate on MR spectroscopy, bilateral basal-ganglia lesions, dysautonomia ("neurostorming"), and, in severe cases, multiorgan failure and death.

Because the lesion is accumulation of a diffusible toxin rather than a fixed structural defect in the respiratory chain, SQORD is explicitly framed as potentially treatable: current management is supportive (prompt treatment of metabolic crises, aggressive treatment of intercurrent illness, avoidance of catabolic triggers), while mechanism-based strategies aim to lower the H₂S burden (pharmacological sulfide scavenging, candidate cobalamin-based scavengers, limiting dietary sulfur/cysteine, and microbiome modulation). The disease was first delineated in 2020 in two families, including a Lehrerleut Hutterite founder mutation (p.Glu213Lys) with a carrier frequency of 1 in 13. Diagnosis rests on exome/genome or Leigh-panel sequencing showing biallelic SQOR variants together with isolated complex IV deficiency and preserved complex IV assembly. Information in this report is derived from aggregated disease-level resources and individual case reports, not from a structured EHR cohort.

Key Findings

Finding 1 — Biallelic SQOR variants cause a treatable Leigh-like mitochondrial disease

The disease entity was established by Friederich et al. (2020) in a study of two families PMID: 32160317. In Family A, two Hutterite sisters were homozygous for SQOR c.637G>A (p.Glu213Lys); they presented with coma, lactic acidosis, multiorgan failure, hypotonia, neurostorming, and Leigh-like basal-ganglia lesions, and both died. In Family B, a boy homozygous for the frameshift variant c.446delT had recurrent (episodic) encephalopathy with basal-ganglia lesions.

The biochemistry pinpointed the mechanism: "Muscle and liver tissue had isolated decreased complex IV activity, but normal complex IV protein levels and complex formation." This dissociation — reduced activity with preserved protein and assembly — is the signature of enzymatic inhibition rather than a structural/assembly defect, pointing directly to a diffusible inhibitor. The authors identified it: "Toxic hydrogen sulfide exposure inhibits complex IV." Enzyme assays confirmed severely reduced SQOR activity and protein. The founder allele was characterized as: "Both patients were homozygous for c.637G > A, which we identified as a founder mutation in the Lehrerleut Hutterite with a carrier frequency of 1 in 13." The report's framing of SQORD as "a potentially treatable cause of Leigh disease" underpins its clinical importance.

Finding 2 — SQOR is the committed first enzyme of H₂S catabolism, and tissue vulnerability tracks SQOR level

SQOR (EC 1.8.5.4) is an inner-mitochondrial-membrane flavoprotein that oxidizes H₂S and transfers electrons to ubiquinone/Coenzyme Q. Transient-kinetic work by Mishanina et al. (2015) PMID: 26318450 showed that "the flavin cofactor is intermittently reduced by sulfide and oxidized by ubiquinone, linking H2S oxidation to the electron transfer chain and to energy metabolism" (bound-flavin redox potential ≈ −123 mV). SQOR therefore both detoxifies H₂S and feeds electrons into the respiratory chain.

The physiological consequence of SQOR abundance was demonstrated across species by Marutani, Ichinose et al. (2021) PMID: 34035265. Comparing mice, rats, and the hypoxia-tolerant 13-lined ground squirrel, they found "the sensitivity of the brain to hypoxia is inversely related to the levels of sulfide:quinone oxidoreductase (SQOR) and the capacity to catabolize sulfide." Silencing SQOR increased hypoxia sensitivity; neuron-specific SQOR expression prevented hypoxia-induced sulfide accumulation, bioenergetic failure, and ischemic injury. Crucially for therapy: "Pharmacological scavenging of sulfide maintained mitochondrial respiration in hypoxic neurons and made mice resistant to hypoxia." This directly links low/absent SQOR activity to the brain's bioenergetic collapse — the core of SQORD — and nominates sulfide scavenging as a rational intervention.

Finding 3 — Consolidated disease and gene identifiers

Verified via OLS4/MONDO and mygene.info.

Finding 4 — Pathway context: ETHE1 (ethylmalonic encephalopathy) is the downstream "mirror" disorder

SQORD sits at the head of the mitochondrial sulfide-oxidation pathway:

H2S → [SQOR] → persulfide (GSSH) → [ETHE1 sulfur dioxygenase] → sulfite
          |                                                         |
     electrons → CoQ / ETC            [sulfite oxidase SUOX / rhodanese TST] → thiosulfate / sulfate

Loss of the downstream enzyme ETHE1 causes ethylmalonic encephalopathy (OMIM #602473), which — like SQORD — produces H₂S accumulation and "decreased activity of the mitochondrial complex IV, which limits energy production in tissues that require a large supply of energy" PMID: 40563372. The shared complex IV defect in two enzymatically distinct disorders of the same pathway corroborates the "H₂S poisons complex IV" mechanism and defines SQORD and ETHE1 deficiency as pathophysiological mirror images (upstream vs. downstream lesions of sulfide catabolism).

Finding 5 — Phenotype spectrum with HPO terms

Official HPO disease annotations for OMIM:619221 (JAX ontology API) plus features reported in Friederich 2020:

The clinical core is captured by the report that the patient "remained comatose, hypotonic, had neurostorming episodes, elevated lactate, and Leigh-like lesions on brain imaging" PMID: 32160317. Onset ranged ~4–8 years; episodes were often triggered by intercurrent illness/catabolic stress; severe cases were rapidly fatal; at least one child had a recurrent/episodic course.

Finding 6 — SQOR pathogenic variants are ultra-rare; LoF tolerated in heterozygosity

A gnomAD v4 query of SQOR (chr15, GRCh38) returned ~2,458 variants. All predicted loss-of-function alleles occur at very low frequencies (~7×10⁻⁷ to ~2.5×10⁻⁵):

No homozygotes for LoF alleles are present in the general population, consistent with severe recessive disease. SQOR tolerates heterozygous LoF (it is a recessive disease gene, not haploinsufficient). The founder missense — "a founder mutation in the Lehrerleut Hutterite with a carrier frequency of 1 in 13" PMID: 32160317 — is essentially absent from outbred populations.

Finding 7 — Treatment rationale and model organisms

No approved disease-specific therapy exists. Management is supportive: treat acute metabolic/lactic crises, avoid catabolic triggers and fasting, and aggressively treat intercurrent illness that precipitates decompensation. Mechanism-based strategies target lowering H₂S: pharmacological sulfide scavenging "maintained mitochondrial respiration in hypoxic neurons and made mice resistant to hypoxia" PMID: 34035265. Candidate approaches include hydroxocobalamin/oxidized cobalamin and other sulfide-binding agents, and limiting sulfur/cysteine load. Gut-microbiome-derived H₂S contributes to total sulfide burden and modulates brain bioenergetics, suggesting dietary/microbiome modulation as an adjunct PMID: 40526718.

Model organisms: mouse (Mus musculus, Sqor NCBI Gene 59010) with SQOR silencing and neuron-specific re-expression recapitulates sulfide accumulation, bioenergetic failure, and brain hypoxia sensitivity PMID: 34035265; the hypoxia-tolerant 13-lined ground squirrel is a comparative high-SQOR model; invertebrate/parasite SQOR (C. elegans; Schistosoma mansoni PMID: 41638445) illustrate conserved enzymology; patient fibroblasts, muscle, and liver were the primary human cellular models.

Finding 8 — Human SQOR has solved experimental structures enabling variant modeling

PDBe best-structures mapping for UniProt Q9Y6N5 returns 8 experimental structures: 6MO6, 6MP5, 6OI5, 6OI6, 6OIB, 6OIC, 6WH6, 8DHK. These define the FAD flavoprotein fold and membrane-interacting/quinone-binding regions, enabling structural rationalization of pathogenic missense alleles — e.g., p.Glu213Lys, which disrupts hydrogen bonding with neighboring residues (Friederich 2020) — and a platform for classifying novel missense VUS (AlphaFold model AF-Q9Y6N5 also available).

Mechanistic Model / Interpretation

Ordered causal chain (initiating lesion → clinical manifestation)

1. Biallelic loss-of-function variants in SQOR (e.g., p.Glu213Lys missense; c.446delT frameshift) lead to loss of functional sulfide:quinone oxidoreductase in the inner mitochondrial membrane. (Demonstrated: reduced SQOR activity + protein in patient tissue.)
2. Loss of SQOR results in failure of the committed first step of mitochondrial H₂S oxidation, so endogenous and gut-derived H₂S cannot be catabolized. (Inferred from enzyme role; directly demonstrated in SQOR-silenced models.)
3. Blocked catabolism leads to accumulation of H₂S (and upstream persulfide species), especially when production rises during intercurrent illness/catabolism (branch point where environment feeds in). (Demonstrated in mouse models; inferred in patients.)
4. Accumulated H₂S inhibits complex IV (cytochrome c oxidase) — an isolated, functional COX defect with normal complex IV protein and assembly. (Demonstrated in patient muscle and liver.)
5. Complex IV inhibition results in blocked oxidative phosphorylation and ATP failure, with a shift to anaerobic glycolysis → lactic acidosis and elevated brain lactate (MRS). (Demonstrated clinically/biochemically.)
6. Bioenergetic failure concentrates in the brain's most metabolically demanding gray matter → bilateral basal-ganglia (Leigh-like) lesions, encephalopathy, coma, seizures, hypotonia, dysautonomia. (Demonstrated by imaging and clinical course.)
7. Catabolic stress raises sulfide flux and energetic demand → episodic metabolic decompensation, progressing to multiorgan failure and death in severe cases. (Demonstrated: infection-triggered, fatal outcomes in Family A.)

Protective counterfactual branch: restoring H₂S clearance (SQOR re-expression) or scavenging sulfide prevents steps 4–8 (shown in neurons/mice; Marutani 2021).

Upstream vs. downstream

• Upstream (primary lesion): SQOR genotype → enzyme loss → H₂S accumulation.
• Downstream (effector): complex IV inhibition → OXPHOS failure → lactic acidosis → basal-ganglia injury → encephalopathy.
• Pathway sibling: ETHE1 deficiency produces the same downstream complex IV defect from a lesion one step below SQOR, confirming the mechanism and the shared therapeutic rationale (lower H₂S).

Ontology annotations

• Biological process (GO): hydrogen sulfide metabolic process (GO:0070813); sulfide oxidation (GO:0019417); oxidative phosphorylation (GO:0006119); cellular respiration (GO:0045333).
• Cellular component (GO): mitochondrion (GO:0005739); mitochondrial inner membrane (GO:0005743).
• Cell types (CL): neuron (CL:0000540), especially basal-ganglia/striatal neurons; astrocyte (CL:0000127); broadly high-OXPHOS cells (myocyte CL:0000187; hepatocyte CL:0000182).
• Anatomy (UBERON): brain (UBERON:0000955), basal ganglia (UBERON:0002420), striatum (UBERON:0002435), brainstem (UBERON:0002298), skeletal muscle (UBERON:0001134), liver (UBERON:0002107).
• Chemical entities (CHEBI): hydrogen sulfide (CHEBI:16136); ubiquinone/CoQ (CHEBI:16389); FAD (CHEBI:16238); L-lactate (CHEBI:16651); thiosulfate (CHEBI:33542); L-cysteine (CHEBI:17561).
• Treatment (NCIT): supportive care (NCIT:C15277); hydroxocobalamin (NCIT:C47707/C47642); sulfide-scavenging agents (investigational).

Section-by-Section Dossier

1. Disease Information

Autosomal-recessive mitochondrial inborn error of H₂S catabolism presenting as a Leigh-like metabolic encephalopathy. Identifiers: MONDO:0030982; OMIM #619221; GARD:0025671; MedGen/UMLS C5543168; no dedicated Orphanet/ICD-specific code (best coded under mitochondrial/metabolic encephalopathy, ICD-10 E88.8; ICD-11 Leigh-syndrome category by phenotype). Synonyms: SQORD; sulfide:quinone oxidoreductase deficiency; SQR deficiency (gene aliases SQRDL, SQR, CGI-44, PRO1975). The knowledge base is disease-level/case-report derived, not EHR-based.

2. Etiology

Primary cause: biallelic pathogenic SQOR variants → loss of function. Genetic risk: carrier status; founder/consanguineous membership (Hutterite carrier 1/13). Environmental triggers of crises (not causes): intercurrent infection, fasting, catabolic stress; dietary sulfur/cysteine and gut-microbiome H₂S add to burden. Protective factors (inferred): higher residual SQOR activity; lower sulfide load. Gene–environment interaction: a fixed genetic enzymatic bottleneck is overwhelmed when H₂S production rises — a threshold GxE interaction precipitating complex IV inhibition.

3. Phenotypes

See Finding 5 table. Types: clinical signs (coma, hypotonia, seizures, dysautonomia), lab abnormalities (lactic acidosis, elevated brain lactate by MRS, elevated CK), imaging (bilateral basal-ganglia/Leigh-like lesions). Onset: childhood (~4–8 y). Severity: variable — fatal metabolic coma to recurrent survivable encephalopathy. Progression: episodic/fluctuating with stepwise injury accrual. QoL impact: profound — intensive-care dependence, death in severe cases, fixed neurological sequelae (dystonia, developmental impairment) in survivors. No formal EQ-5D/SF-36/PROMIS data exist.

4. Genetic / Molecular Information

Causal gene: SQOR (15q21.1), ~450-aa FAD flavoprotein on the inner mitochondrial membrane. Reported variants: c.637G>A p.Glu213Lys (destabilizing missense, founder, LoF-equivalent) and c.446delT p.Leu149ArgfsTer18 (frameshift/null). Population nulls (p.Arg267Ter, p.Arg139Ter) ultra-rare, no homozygotes. Classification: pathogenic (segregation, founder data, functional enzyme loss, complex IV biochemistry). Consequence: loss of function; germline origin. Modifiers: none established (plausibly ETHE1, TST, SUOX, CBS, CTH, MPST). SQOR is an NRF2 target (36758466), relevant to expression regulation but not a described modifier. Epigenetics / chromosomal abnormalities: none reported.

5. Environmental Information

Non-genetic modulators rather than causes: intercurrent illness and catabolic stress trigger crises; dietary sulfur/cysteine and gut-microbiome H₂S (e.g., Desulfovibrio spp.) add to sulfide burden PMID: 40526718. Exogenous H₂S is the toxicological analogue (H₂S inhibits complex IV). No infectious etiology.

6. Mechanism / Pathophysiology

See the ordered causal chain above. Core pathway: SQOR loss → H₂S accumulation → complex IV inhibition → OXPHOS failure → lactic acidosis + basal-ganglia injury → encephalopathy. Supported by isolated functional complex IV deficiency with normal assembly (PMID: 32160317), SQOR enzymology (PMID: 26318450), the SQOR-level/hypoxia-sensitivity relationship (PMID: 34035265), and the ETHE1 pathway mirror (PMID: 40563372). No dedicated patient omics cohort exists; functional assays are SQOR activity, western blot, respirometry, and complex IV activity.

7. Anatomical Structures Affected

Primary organ: brain (basal ganglia, brainstem; Leigh-like). Secondary: skeletal muscle and liver (biochemical COX deficiency); multiorgan failure in crises. Body systems: nervous (primary), musculoskeletal, hepatic, cardiovascular (during decompensation), autonomic. Subcellular: mitochondrion / inner mitochondrial membrane. Lateralization: bilateral, often symmetric basal-ganglia involvement.

8. Temporal Development

Onset: childhood (~4–8 y), acute/subacute, infection-triggered; a milder later spectrum possible (migraine annotation). Course: episodic/relapsing with stepwise accrual; rate from fulminant/fatal to recurrent over years. Duration: lifelong susceptibility. Critical periods: intercurrent infection/fasting (vulnerability) and the acute crisis (narrow window for metabolic rescue).

9. Inheritance and Population

Inheritance: autosomal recessive (HP:0000007). Penetrance: high/complete for biallelic null genotypes; expressivity variable (fatal vs recurrent). Epidemiology: ultra-rare; precise prevalence/incidence unknown; enriched in founder/consanguineous groups. Founder/carrier frequency: Lehrerleut Hutterite 1/13 for c.637G>A; no LoF homozygotes in gnomAD. Consanguinity: increases risk. Anticipation/germline mosaicism: not applicable/not reported. Demographics: pediatric; both sexes (no sex bias expected).

10. Diagnostics

Genetic testing (first-line, confirmatory): WES/WGS or mitochondrial/Leigh nuclear-gene panel including SQOR; targeted founder-variant/cascade testing in Hutterite families; mtDNA testing to exclude mtDNA Leigh syndrome. CMA/karyotype/FISH/repeat testing not indicated. Biochemical: isolated decreased complex IV activity with normal complex IV protein/assembly (key discriminator); reduced SQOR activity/protein; lactic acidosis; elevated CK; candidate urinary thiosulfate/sulfur-metabolite biomarkers (needs validation). Imaging: MRI bilateral basal-ganglia (± brainstem/cortical) Leigh-like lesions; MRS lactate peak. Differential diagnosis: mtDNA/nuclear Leigh syndrome (SURF1, MT-ATP6); ETHE1 ethylmalonic encephalopathy (distinguished by ethylmalonic aciduria, acrocyanosis/petechiae, chronic diarrhea); other pediatric lactic-acidosis/metabolic-coma causes. Screening: cascade carrier testing in founder populations; prenatal/PGT for known familial variants; not in standard newborn screening.

11. Outcome / Prognosis

Guarded: both Family A sisters died; the Family B boy had recurrent encephalopathy. Survivors risk fixed neurological sequelae from basal-ganglia injury; recurrent crises drive cumulative disability. Complications: metabolic coma, status epilepticus, multiorgan failure, aspiration, dysautonomia. Recovery: crisis recovery possible with prompt metabolic management; genetic defect persists (lifelong risk). Prognostic factors: genotype/residual activity, age at first crisis, speed of rescue, trigger burden; extent of lactate elevation and basal-ganglia injury on MRI.

12. Treatment

No approved disease-specific therapy; care is supportive + mechanism-based/investigational. Supportive (NCIT:C15277): treat lactic acidosis, provide anti-catabolic/glucose support, avoid fasting, aggressively treat infections, ICU support; empirical mitochondrial cofactor "cocktail." Mechanism-based (investigational): sulfide scavenging (preclinical support, PMID: 34035265); hydroxocobalamin/cobalamin sulfide-binding species; dietary sulfur/cysteine restriction; gut-microbiome modulation PMID: 40526718. Advanced therapeutics (not developed): gene therapy/enzyme replacement conceptually attractive; no gene/cell/RNA/targeted/immunotherapy exists. Surgical/pharmacogenomics: none. Trials: no SQORD-specific registered trials identified.

13. Prevention

Primary: genetic counseling and carrier/cascade screening in founder/consanguineous populations (Hutterite 1/13); preconception/prenatal/PGT for known variants. Secondary: early molecular diagnosis in at-risk sibs; prompt crisis recognition; avoid fasting. Tertiary: aggressive infection management, "sick-day" protocols, and investigational H₂S-lowering to prevent recurrent injury. Counseling: 25% recurrence risk per pregnancy for carrier couples. Immunization/public health: childhood immunization reduces infectious triggers; avoid exogenous sulfide.

14. Other Species / Natural Disease

SQOR is deeply conserved (bacteria→mammals). Orthologs: mouse Sqor (NCBI Gene 59010, NCBITaxon:10090), rat (10116), zebrafish (7955), C. elegans (6239), Schistosoma mansoni (6183). No naturally occurring Mendelian SQOR-deficiency disease catalogued in OMIA. Comparative biology: sulfide-tolerant organisms (S. mansoni in sulfide-rich mesenteric veins, PMID: 41638445; C. elegans rhodoquinone chain in sulfide) and high-SQOR hypoxia-tolerant ground squirrels illustrate conserved sulfide-defense biology. Not zoonotic/transmissible.

15. Model Organisms

Mouse (silencing + neuron-specific re-expression) recapitulates sulfide accumulation, bioenergetic failure, and brain hypoxia sensitivity (PMID: 34035265); links gut sulfide to brain bioenergetics (PMID: 40526718). Comparative: 13-lined ground squirrel (high-SQOR, protected). Invertebrate/microbial: C. elegans, S. mansoni, bacterial SQR for conserved enzymology. In vitro/cellular: patient fibroblasts, muscle, liver; hypoxic primary neurons for scavenging rescue. Phenotype recapitulation: strong for mechanism/tissue vulnerability; a faithful constitutive-knockout replicating the full triggered episodic Leigh-like crisis phenotype is not well established (a key gap). Resources: MGI (Sqor), Alliance of Genome Resources, IMPC/KOMP.

Evidence Base

Evidence source types: human clinical/biochemical (Friederich 2020), model organism (Marutani 2021; ETHE1 cellular models), in vitro enzymology (Mishanina 2015), and database/computational (gnomAD v4, OLS4/MONDO, mygene.info, JAX HPO API, PDBe).

Supported hypotheses: (1) biallelic SQOR LoF causes an AR Leigh-like disease; (2) mechanism = H₂S accumulation → complex IV inhibition → energy failure (isolated functional COX defect with normal assembly); (3) ultra-rare, founder-enriched (Hutterite 1/13); (4) childhood-onset, episodic, infection-triggered; (5) "potentially treatable" via H₂S lowering (preclinical support).

Refuted / excluded: complex IV deficiency is not a structural/assembly defect (protein and assembly normal); not mtDNA-encoded; SQOR is not haploinsufficient (heterozygous LoF tolerated); not associated with common population variants, CNVs, or disease-specific epigenetic lesions.

Limitations and Knowledge Gaps

• Very small evidence base. The disease rests primarily on two families (three patients) from a single 2020 report. Prevalence, incidence, full phenotype spectrum, penetrance, expressivity, and natural history outside the Hutterite founder context are essentially unknown; the migraine annotation hints at an under-recognized milder spectrum.
• No approved therapy and no clinical-trial data. Sulfide-scavenging and cobalamin-based strategies rest on preclinical/mechanistic data only; efficacy, dosing, and safety in SQORD patients are untested.
• Indirect in-patient H₂S measurement. Human-tissue H₂S accumulation is inferred from complex IV biochemistry and model-organism data rather than directly quantified.
• No validated routine biomarker. Urinary thiosulfate/sulfur metabolites need validation specifically for SQORD.
• No crisis-faithful knockout disease model. Existing mouse work used silencing/re-expression focused on hypoxia, not a constitutive knockout reproducing the triggered episodic phenotype.
• No dedicated omics datasets (transcriptomic/proteomic/metabolomic) for patients; no Orphanet/ICD-specific entry.
• Modifier genes and genotype–phenotype correlations are not established.

Proposed Follow-up Experiments / Actions

1. Establish a patient/variant registry (GeneMatcher, clinician networks) to identify additional SQORD cases and define phenotype spectrum, penetrance, and natural history.
2. Build a faithful Sqor-knockout (and p.Glu213Lys knock-in) mouse, plus patient-iPSC-derived neurons/organoids, to quantify H₂S accumulation, complex IV inhibition, and basal-ganglia vulnerability, and to serve as a therapeutic testbed.
3. Preclinical efficacy testing of sulfide-lowering interventions — pharmacological scavengers, hydroxocobalamin/oxidized cobalamin, dietary sulfur/cysteine restriction, and microbiome modulation — with respiration/ATP and survival endpoints.
4. Develop and validate biomarkers of sulfide burden (plasma/urine thiosulfate, sulfide/persulfide species, brain-lactate MRS) for diagnosis, crisis prediction, and treatment monitoring.
5. Structure-guided variant classification using the 8 solved human SQOR structures and AlphaFold to triage novel missense VUS by predicted effect on FAD binding, quinone access, and membrane interaction.
6. Carrier-screening and crisis-prevention protocols for founder/consanguineous populations (Hutterite p.Glu213Lys), including "sick-day" management guidelines to pre-empt catabolic decompensation.

Report compiled from eight confirmed findings across five investigation iterations and 23 reviewed papers. Evidence is strongest for the gene–enzyme–mechanism axis (SQOR loss → H₂S accumulation → complex IV inhibition → Leigh-like encephalopathy) and weakest for epidemiology and therapy, which remain to be defined. Only attributions supported by the cited abstracts/snippets are made; titles alone were not used to infer paper content.